Archive for July, 2008

post thumbnail

Clinical Trial Recruitment | Retention Issues for Manufacturers of Diabetes Agents

Clinical Trial Recruitment | Retention
Anxiety lurks among manufacturers of type 2 diabetes drugs, especially those manufacturers who have drugs in late clinical development. 
Recent FDA advisory committee recommendations have created an ongoing debate over whether Investigational diabetes agents should be subject to long-term cardiovascular safety. 1   A firm consensus has not been reached,  however, several manufacturers [...]

31Jul2008 | admin | 0 comments | Continued
post thumbnail

OmniTrace Patient Locate Services

Patient Locate
We’d like to provide you additional information about OmniTrace Corp. and our patient locate services. 
Who Are We?
OmniTrace Corporation, a licensed and bonded private investigation agency, headquartered in Boca Raton, Florida, established in 2001, is the premier patient locate service provider to the clinical trial industry.
In the USA, Europe, South America and elsewhere, OmniTrace locates Lost [...]

14Jul2008 | admin | 0 comments | Continued
post thumbnail

Find Patients Lost To Follow-Up

OmniTrace Corp. - The Patient Search Experts.  We maximize clinical trial success by greatly reducing patients Lost To Follow-Up.  We find patients and clinical trial participants who become missing anywhere in the world.  In addition to our patient locate service, we offer

13Jul2008 | admin | 0 comments | Continued
post thumbnail

HIPAA: Clinical Study Conduct When Searching For Patients Lost To Follow-Up

Much information exists about HIPAA–a multifaceted legislation covering the insurance portability and fraud enforcement (accountability) acts.  However, the guidance for privacy and security laws are vague, particularly regarding:

Clinical study conduct and searching for patients that have prematurely dropped out and are lost to follow-up
How HIPAA affects long-term follow-up (pharmacovigilance) programs encourage by the FDA for subjects in [...]

13Jul2008 | admin | 0 comments | Continued